gkap1 Antibody

What is GKAP1 and what cellular functions does it serve?

GKAP1 (G Kinase Anchoring Protein 1) is a scaffold protein that plays pivotal roles in multiple signaling pathways. It primarily functions as a key adaptor protein of glutamate-activated N-methyl-D-aspartate receptors (NMDARs), regulating synaptic plasticity in neuronal contexts. In cellular localization studies, GKAP1 is predominantly found in the Golgi apparatus. Beyond neuronal functions, GKAP1 has been implicated in germ cell development, with its mRNA specifically expressed in testis, particularly in spermatocytes and early round spermatids . Recent research has revealed its significant involvement in governing invasive growth in various cancer types through its regulation of NMDAR pathway activity .

What are the validated applications for GKAP1 antibodies?

GKAP1 antibodies have been validated for multiple experimental applications:

• Western Blot (WB): Validated at dilutions of 1:500-1:1000, with positive detection in HEK-293 cells and mouse testis tissue

• Immunohistochemistry (IHC): Validated at dilutions of 1:20-1:200, with positive detection in human cervical cancer tissue and human testis tissue

• Immunofluorescence (IF): Validated in published literature

• ELISA: Validated in multiple antibody formulations

For optimal results, tissue-specific antigen retrieval methods are recommended: TE buffer at pH 9.0 or citrate buffer at pH 6.0 for IHC applications .

What is the molecular weight range for GKAP1 in Western blot applications?

While the calculated molecular weight of GKAP1 is 42 kDa (from its 366 amino acid sequence), experimental observations consistently report detecting GKAP1 at 45-50 kDa in Western blot applications . This discrepancy between calculated and observed molecular weight likely reflects post-translational modifications. When validating a new GKAP1 antibody, researchers should expect bands in this molecular weight range rather than precisely at 42 kDa. For Western blot optimization, recommended antibody concentrations are typically around 1 μg/ml when using commercially available antibodies .

How should I optimize GKAP1 antibody selection for detection of GKAP1-NTRK2 fusions?

When investigating GKAP1-NTRK2 fusions, antibody selection requires careful consideration of epitope location. The GKAP1-NTRK2 fusion described in literature joins GKAP1 exon 10 to NTRK2 exon 16, creating a 658 amino acid fusion protein with retained tyrosine kinase (TK) domain . For detecting such fusions:

• Choose antibodies targeting the N-terminal region of GKAP1 (AA 21-366) to ensure the epitope is preserved in the fusion protein

• Pair with phospho-specific antibodies against the NTRK2 tyrosine kinase domain (e.g., phospho-TrkB (Tyr705)) to simultaneously confirm fusion protein expression and activation

• Validate using both Western blot and functional assays to assess downstream pathway activation (pERK, pAKT, pS6)

This dual-detection approach allows confirmation of both the fusion presence and its functional activation.

What controls should be included when studying GKAP1 expression in different genetic backgrounds?

Research shows GKAP1 expression levels vary significantly between genetic backgrounds, affecting downstream signaling pathways. Based on studies in different mouse strains (B6 vs. C3H), comprehensive controls should include:

• Positive tissue controls: Mouse testis tissue shows reliable GKAP1 expression

• Genetic background controls: Include samples from multiple genetic backgrounds when possible, as SNP variations can affect transcription factor binding (e.g., HSF1) and GKAP1 expression levels

• Pathway activation controls: Measure p-GluN2b (Y1252) alongside GKAP1, as GKAP1 levels correlate with NMDAR activation despite similar receptor expression levels

• Downstream effector controls: Include FMRP and p-HSF1 measurements, as these are modulated by GKAP1-dependent signaling

This comprehensive approach allows proper interpretation of results across different genetic contexts and provides internal validation of antibody specificity.

What sample preparation methods maximize GKAP1 antibody specificity in complex tissue samples?

For optimal GKAP1 detection in complex tissues like brain tumors or testis, specific preparation techniques enhance signal-to-noise ratio:

• Fixation optimization: For IHC applications, formalin-fixed paraffin-embedded (FFPE) tissues require specific antigen retrieval - TE buffer at pH 9.0 yields superior results compared to citrate buffer at pH 6.0

• Cell-specific enrichment: For heterogeneous tissues, consider FACS purification before analysis, as studies show β tumor cells are the major GKAP1-expressing population compared to stromal cells

• Special considerations for fusion detection: When examining potential GKAP1 fusion proteins, fresh frozen tumor material has proven more effective than FFPE for initial molecular characterization

• PCR confirmation strategy: For low-abundance samples, implement nested PCR approaches as demonstrated in the GKAP1-NTRK2 fusion detection protocol

These methodological refinements significantly improve detection sensitivity while maintaining specificity across different experimental contexts.

How can GKAP1 antibodies be used to interrogate NMDAR signaling pathway activation in cancer models?

GKAP1 functions as a key modifier of NMDAR signaling, particularly in cancer contexts. Advanced research protocols utilizing GKAP1 antibodies include:

• Co-immunoprecipitation assays: Use GKAP1 antibodies to pull down protein complexes, followed by immunoblotting for NMDAR subunits (GluN1, GluN2b) and downstream effectors

• Proximity ligation assays: Combine GKAP1 antibodies with NMDAR subunit antibodies to visualize and quantify complex formation in situ

• Chromatin immunoprecipitation sequencing (ChIP-seq): Examine HSF1 binding at the GKAP1 locus, as HSF1 has been identified as an upstream regulator of GKAP1 expression

• Multi-parameter analysis: Combine GKAP1 IHC with p-GluN2b, HSF1, and FMRP staining in serial tissue sections to establish pathway activation status

This multi-method approach provides comprehensive assessment of NMDAR-GKAP1 pathway activity across different experimental systems and tumor types.

What methodological approaches reveal the relationship between GKAP1 expression and invasive tumor growth?

Research demonstrates that GKAP1 governs invasive growth programs in multiple cancer types. To investigate this relationship:

• Knockdown validation: Confirm antibody specificity through GKAP1 knockdown experiments, which should show corresponding reduction in detected protein levels

• Pharmacological intervention studies: Combine GKAP1 expression analysis with NMDAR inhibitor treatments (e.g., MK801) to evaluate pathway dependency

• Invasion assay correlation: Pair GKAP1 expression levels with quantitative invasion assays, including flow-condition assays that better simulate in vivo conditions

• Tissue microarray analysis: Use validated GKAP1 antibodies on TMAs containing primary tumors and metastases to establish clinical correlations - studies show progressive elevation from primary pancreatic ductal adenocarcinoma (PDAC) to lymph node metastases

These approaches collectively establish both mechanistic and clinical relationships between GKAP1 expression and invasive tumor phenotypes.

How can functional validation of GKAP1 fusion proteins be established using antibody-based methods?

For rigorous functional validation of GKAP1 fusion proteins:

• Transient transfection systems: Express the fusion protein (e.g., GKAP1-NTRK2) alongside wild-type controls in model systems like HEK293 cells

• Phosphorylation status assessment: Validate fusion protein activation using phospho-specific antibodies targeting relevant domains (e.g., phospho-TrkB (Tyr705))

• Downstream signaling quantification: Measure MAPK and PI3K pathway activation through quantitative Western blot using the following antibodies:

  • Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)

  • Phospho-Akt (Ser473)

  • Phospho-S6 Ribosomal Protein (Ser235/236)

• Inhibitor response validation: Confirm functional relevance by treating fusion-expressing cells with targeted inhibitors (e.g., larotrectinib for NTRK fusions) and measuring pathway inhibition

This systematic approach provides conclusive evidence of fusion protein functionality and potential therapeutic targetability.

How can I resolve inconsistent GKAP1 antibody staining patterns in different tissue types?

Differential GKAP1 expression across tissues requires protocol optimization:

• Genetic background assessment: GKAP1 expression varies significantly by genetic background due to SNP variations affecting transcription factor binding

• Buffer optimization: For IHC applications, compare TE buffer (pH 9.0) versus citrate buffer (pH 6.0) for antigen retrieval, as optimal conditions vary by tissue type

• Epitope accessibility evaluation: For Golgi-localized GKAP1, ensure permeabilization methods are sufficient - use Triton X-100 (0.1-0.5%) for optimal intracellular epitope access

• Cross-validation approach: Employ multiple GKAP1 antibodies targeting different epitopes (N-terminal vs. C-terminal regions) to distinguish genuine expression patterns from artifacts

These technical refinements address the common challenges in achieving consistent GKAP1 detection across diverse experimental contexts.

What strategies can resolve discrepancies between GKAP1 mRNA and protein expression levels?

Studies have documented cases where GKAP1 mRNA levels remain unchanged while protein levels decrease significantly after experimental interventions . To investigate such discrepancies:

• Post-translational regulation assessment: Combine GKAP1 antibody detection with ubiquitination assays to evaluate protein degradation

• Translational control investigation: Evaluate FMRP involvement, as FMRP has been implicated in translational regulation downstream of NMDAR signaling

• Subcellular fractionation: Use organelle-specific markers alongside GKAP1 antibodies to track potential protein redistribution rather than degradation

• Phosphorylation status: Include phospho-specific antibodies to assess whether post-translational modifications affect epitope recognition or protein stability

This multi-faceted approach differentiates between transcriptional, translational, and post-translational mechanisms affecting GKAP1 expression.

How can GKAP1 antibodies contribute to precision medicine approaches for NTRK fusion-positive cancers?

The discovery of GKAP1-NTRK2 fusions in pediatric low-grade gliomas has therapeutic implications:

• Diagnostic screening protocol: Develop IHC-based screening protocols using GKAP1 and phospho-TrkB antibodies to identify potential fusion-positive cases for confirmation by molecular methods

• Response prediction biomarkers: Monitor GKAP1 expression alongside downstream pathway activation (pERK, pAKT, pS6) to predict and assess response to TRK inhibitors like larotrectinib

• Resistance mechanism investigation: In cases developing resistance to TRK inhibitors, use GKAP1 antibodies to assess potential alterations in fusion protein expression or localization

• Liquid biopsy development: Explore the potential for detecting circulating GKAP1-fusion proteins using highly specific antibodies in minimally invasive monitoring approaches

These applications bridge basic research findings to clinical applications, potentially improving precision medicine approaches for NTRK fusion-positive cancers.

What methodological advances enable single-cell analysis of GKAP1 expression in heterogeneous tumors?

Emerging techniques for single-cell level GKAP1 analysis include:

• Mass cytometry (CyTOF): Conjugate GKAP1 antibodies with metal isotopes for high-dimensional analysis alongside other pathway components

• Imaging mass cytometry: Combine GKAP1 antibodies with spatial information to map expression in the tumor microenvironment

• Single-cell Western blot: Adapt validated GKAP1 antibody protocols for microfluidic-based single-cell protein analysis

• In situ proximity ligation assays: Detect GKAP1 interactions with binding partners at single-cell resolution within tissue contexts

These advanced methodologies overcome the limitations of bulk analysis, revealing cell-specific GKAP1 expression patterns and pathway activation states within heterogeneous tumor environments.

How can GKAP1 antibodies be integrated into multi-omic research approaches?

For comprehensive system-level understanding:

• Spatial transcriptomics integration: Correlate GKAP1 protein localization (by IHC/IF) with spatial transcriptomic data to reveal microenvironmental influences

• Phospho-proteomics correlation: Combine GKAP1 antibody-based pulldowns with phospho-proteomic analysis to map the complete signaling network

• ChIP-seq correlation: Integrate GKAP1 expression data with HSF1 ChIP-seq to establish transcriptional regulatory mechanisms

• Patient-derived organoid validation: Apply validated GKAP1 antibody protocols to patient-derived organoids to bridge genomic findings with functional studies